Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Zhaoke Ophthalmology Ltd. ( (HK:6622) ) has shared an update.
Zhaoke Ophthalmology Limited has scheduled a board meeting for March 25, 2026, to review and approve the annual results for the year ended December 31, 2025, and to authorize their publication. The announcement signals the forthcoming release of the company’s full-year financial performance, a key disclosure for investors assessing its operational progress and governance oversight.
The board composition, including executive, non-executive, and independent non-executive directors, underlines the company’s established corporate governance structure. This upcoming results announcement will provide the market with updated insight into Zhaoke Ophthalmology’s business trajectory and may influence investor sentiment toward the stock.
The most recent analyst rating on (HK:6622) stock is a Hold with a HK$3.50 price target. To see the full list of analyst forecasts on Zhaoke Ophthalmology Ltd. stock, see the HK:6622 Stock Forecast page.
More about Zhaoke Ophthalmology Ltd.
Zhaoke Ophthalmology Limited is a Hong Kong-listed company focused on ophthalmic healthcare, overseen by a board comprising executive, non-executive, and independent non-executive directors. The company operates through Zhaoke Ophthalmology and its subsidiaries, with governance led by Chairman Dr. Li Xiaoyi.
Average Trading Volume: 829,371
Technical Sentiment Signal: Buy
Current Market Cap: HK$1.88B
See more data about 6622 stock on TipRanks’ Stock Analysis page.